Agoraphobia
Fear or avoidance of ≥2 of 5 situations (transit, open spaces, enclosed spaces, crowds, outside home alone) due to fear of escape difficulty or incapacitation.
Also known as: agoraphobia
Overview
DSM-5-TR: marked fear or anxiety about being in ≥2 of 5 specific situations — (1) using public transportation, (2) being in open spaces (parking lots, bridges), (3) being in enclosed places (stores, theaters), (4) standing in line or being in a crowd, (5) being outside the home alone. The person fears that escape may be difficult or help unavailable in the event of incapacitating or embarrassing symptoms (e.g., panic, falling, incontinence). Situations almost always provoke fear, are avoided or endured with distress or require a companion, persist ≥6 months with impairment. Now a standalone diagnosis (separate from panic disorder).
Epidemiology
12-month US prevalence ~1.7% in adolescents and adults; lifetime ~1-2%. Female predominance ~2:1. Bimodal onset: late adolescence/early adulthood and after age 40.
Keep reading — start your free trial
You've read your 2 free diagnosis previews. Create your free account to unlock the full Agoraphobia outline — plus all 514 diagnoses, 5,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Risk factors
- History of panic attacks or panic disorder
- First-degree family history of anxiety disorders
- Behavioral inhibition / neuroticism
- Childhood adversity, separation events
- Stressful life event preceding onset
Pathophysiology
Conditioned avoidance after panic or panic-like symptoms in situational contexts. Amygdala hyperactivity and impaired safety-learning in prefrontal-amygdala circuits.
Clinical presentation
Symptoms
- Avoidance of multiple specific public situations
- May require companion to leave home, sit near exits, plan routes
- Anticipatory anxiety with marked physiologic symptoms on exposure
- Housebound in severe cases
- Often comorbid panic attacks (with or without panic disorder)
Signs / physical exam
- Tachycardia, diaphoresis, tremor, hyperventilation during exposure
- Otherwise normal exam
Differential diagnosis
- Panic disorder — Unexpected panic attacks ± concern about future attacks; agoraphobia may coexist but is now a separate diagnosis
- Social anxiety disorder — Fear of social evaluation, not of escape difficulty or incapacitation
- Specific phobia, situational type — Fear of one situation (e.g., flying) rather than ≥2 of the 5 agoraphobic situations
- Separation anxiety disorder — Fear about separation from attachment figures rather than about the situation itself
- PTSD — Avoidance linked to trauma reminders
- Major depressive disorder with avoidance — Avoidance driven by anhedonia/amotivation rather than fear
- Medical: vestibular dysfunction, orthostatic intolerance, cardiac arrhythmia — Realistic concern about incapacitation — workup before diagnosing agoraphobia
Diagnostic workup
Diagnostic criteria
DSM-5-TR: fear/anxiety about ≥2 of the 5 agoraphobic situations; fear of escape difficulty or unavailability of help; situations almost always provoke anxiety; avoidance/endurance/companion; ≥6 months; impairment; not better explained by another disorder.
Labs
- TSH, CMP, CBC
- Cardiac evaluation (ECG ± Holter) if syncope or palpitations dominate
- Vestibular evaluation if dizziness prominent
Imaging
- Not routinely indicated
Diagnostic algorithm
| Feature | Agoraphobia | Panic disorder | Social anxiety disorder |
|---|---|---|---|
| Core fear | Escape difficulty / incapacitation in public situations | Recurrent unexpected panic attacks | Negative social evaluation |
| Triggers | ≥2 of 5 agoraphobic situations | Unexpected; may be uncued | Social/performance situations |
| Avoidance | Multiple public situations, may be housebound | Variable; may overlap with agoraphobia | Social/performance contexts |
| First-line tx | CBT + SSRI/SNRI | CBT + SSRI/SNRI | CBT + SSRI/SNRI |
| Beta-blocker role | Not effective | Not first-line | Performance subtype only |
Treatment
First-line
- Cognitive behavioral therapy with in-vivo exposure (most effective, durable)
- SSRIs (sertraline, escitalopram, paroxetine) or SNRI (venlafaxine ER) — start low to avoid initial activation
- Combined CBT + SSRI for moderate to severe presentations
Second-line / adjunct
- Switch SSRI/SNRI class if inadequate response after 8-12 weeks
- Tricyclics (imipramine, clomipramine) effective but worse tolerability
- Benzodiazepines (clonazepam, lorazepam) — short-term bridge only; can interfere with exposure learning
- Beta-blockers do not treat agoraphobia
Complications
- Severe disability — up to one-third become housebound
- Major depression (very high comorbidity)
- Substance use disorders, especially alcohol
- Loss of employment and social network
- Suicidal ideation
PANCE pearls
- Agoraphobia is now diagnosable independent of panic disorder; comorbidity is common but separable.
- The fear is of escape difficulty or incapacitation, NOT of social judgment — that distinction separates agoraphobia from SAD on exam questions.
- Start SSRIs at half the usual starting dose in anxiety disorders to avoid initial activation that drives discontinuation.
- Exposure works best when the patient does NOT use safety behaviors (companion, water bottle, benzodiazepine) — these maintain the avoidance pattern.
- Always rule out cardiac, vestibular, and endocrine contributors when avoidance centers on physical symptoms.
References
- DSM-5-TR — American Psychiatric Association. DSM-5-TR. 2022.
- NICE CG113 — National Institute for Health and Care Excellence. Generalised Anxiety Disorder and Panic Disorder in Adults: Management. CG113, 2011.
- APA 2009 — American Psychiatric Association. Practice Guideline for the Treatment of Patients with Panic Disorder, 2nd ed.
Practice Psychiatry/Behavioral questions on FirstPassPA
Turn this outline into retention. 5,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Start studying free → Browse all 514 diagnosesEducational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.